Cargando…
Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study
A COVID-19 booster vaccination is being comprehensively evaluated globally due to the emerging concern of reduced protection rate of previous vaccination and circulating Variants of Concern (VOC). But the safety and immunogenicity of homologous BBIBP-CorV boosting vaccination are yet to be thoroughl...
Autores principales: | Ai, Jingwen, Zhang, Yi, Zhang, Haocheng, Zhang, Qiran, Fu, Zhangfan, Lin, Ke, Song, Jieyu, Zhao, Yuanhan, Fan, Mingxiang, Wang, Hongyu, Zhou, Yang, Chen, Xiaohua, Qiu, Chao, Zhang, Wenhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881062/ https://www.ncbi.nlm.nih.gov/pubmed/35034582 http://dx.doi.org/10.1080/22221751.2022.2025746 |
Ejemplares similares
-
Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals
por: Mallah, Saad I., et al.
Publicado: (2023) -
BBIBP-CorV: Hepatitis: case report
Publicado: (2022) -
BBIBP-CorV: Anterior uveitis: case report
Publicado: (2022) -
Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
por: Jeewandara, Chandima, et al.
Publicado: (2022) -
BBIBP-CorV: Steven-Johnson syndrome : case report
Publicado: (2022)